Evidence map›Paper›PMID 39822556›Full record

ArticleAmerican journal of translational research2024

Efficacy and safety of a proprietary

Arunkanth Krishnakumar, Dinesh Kumar Chellappan, Shankaranarayanan Jeyakodi, Meena Dalal, Sohandas Shetty

Abstract read
In one paragraph

Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arunkanth KrishnakumarZeus Hygia Life Sciences 47, Balanagar, Hyderabad, Telengana 500037, India.
Dinesh Kumar ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University (IMU) Bukit Jalil, Kuala Lumpur 57000, Malaysia.
Shankaranarayanan JeyakodiZeus Hygia Life Sciences 47, Balanagar, Hyderabad, Telengana 500037, India.
Meena DalalTrial Guna Private Limited 476, JP Nagar, Bangalore 560083, India.
Sohandas ShettyTrial Guna Private Limited 476, JP Nagar, Bangalore 560083, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe concept of beauty from within is a growing trend in the market and people now look for oral supplements that can enhance the well-being of skin from within. Within this principle, a proprietary pomegranate extract (Grantria

methodsThis evaluation was carried out as a randomized, placebo-controlled clinical study for 60 days at a daily dose of 300 mg. This study involved a total of 60 subjects randomized in the ratio of 1:1 to test group and placebo group. Multiple skin health parameters were evaluated before and after the intervention.

resultsData from this study indicated that

conclusionsGrantria

Indexed as

GrantriaPunica granatumskin healthskin radiancetactile roughnesswrinkles

Identifiers

PMID39822556
PMCPMC11733350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.